Crossmark

Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s12985-025-02899-0

Published Online: 2025-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Nicole Jean

Katsuyama, Eric Shih

Fukunaga, Christian Ken

Neto, Wilson Falco

Coan, Ana Carolina Covre

Faria, Hilaria Saugo

Medeiros, Eduardo Alexandrino
Funding

Funding for this research was provided by:

Conselho Nacional de Desenvolvimento Científico e Tecnológico
License Information

Text and Data Mining valid from 2025-08-21

Version of Record valid from 2025-08-21
More Information

Article History

Received: 7 April 2025

Accepted: 26 July 2025

First Online: 21 August 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below